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SDES with bioresorbable polymer in this setting are limited and therefore the
NOBORI-CTO registries were conducted.
Methods: In 2 large, prospective, multi-center registries, 504 out of 14134 patients
treated with Nobori DES had at least one CTO lesion revascularized. All adverse
events were adjudicated by an independent clinical event committee. The primary
endpoint was Target Lesion Failure (TLF) at 1 year.
Results: CTOpatientswere 6011 years old, 82.9%males, having priorMI, prior PCI and
previous cardiac surgery in 46.9%, 27.9% and 6.4% of patients. Multiple vessels were
treated in 35.5% of patients (2.161.40 lesions per patient) with an average 1.490.77
stents per lesion. Antegrade approach and single wire techniquewere most frequent choice.
Other techniques used included CTO dedicated wires, OTW balloon, microcatheter, rota-
tional atherectomy and cutting balloon. Mean diameter stenosis before procedure was
9116% and TIMI 0 and 1were recorded in 59% of the all lesions treated (not all were
CTO).Mean ﬂuoro timewas 3738minutes and contrast volumewas 276135mL. After
proceduremean diameter stenosis was 717%andTIMI 0 and 1were observed in only 3%
of the lesions. Up to 1-month, there was 1death, 3MIs (0.6%) and no TLR. Four CD (1.2%)
and three TLRs (0.9%)were reported up to one year follow-upbringing the total TLF rate to
2.4%. Target vessels non-target lesion revascularizations were performed in 2 patients
(0.6%). Only one probable subacute stent thrombosis (0.2%) occurred. In the cohort of
patients followed at 3-year, 3 patients suffered a CD (3.1%), 1 had an MI (1.0%), 3
underwent TLR (3.1%) and TLF rate was 6.2% with no late or very late stent thrombosis.
Conclusions:Treatment ofCTOwithNoboriDESshowedexcellent outcomes. Particularly
appealing is that stent thrombosis was very rare despite the multiple overlapping stents. The
low rate of procedural complications and adverse events up to 3 years suggests that this stent
is a valuable treatment option for patients with CTOwho are considered candidates for PCI.
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Background: In-stent restenosis (ISR) chronic total occlusion (CTO) lesions have been
known to be themost challenging subsets for percutaneous coronary intervention among the
CTO population. There have been few reports about ISR CTO intervention. Therefore, we
compared the success rates and long-term outcomes after PCI between ISR and de novo
CTO lesions.
Methods: The data for 368 patients undergoing intervention for CTO from 1998 to
2008 were analyzed. We compared the target lesion revascularization (TLR) success
rate and 5-years follow up outcomes including major adverse cardiovascular and
cerebrovascular event (MACCE) between the patients underwent PCI for ISR CTO
(n¼40) and de novo CTO (n¼328) lesion. TLR success was deﬁned as recovery of
Thrombolysis in Myocardial Infarction (TIMI) grade 3 and residual stenosis diameter
below 30%.
Results: No signiﬁcant difference was observed in clinical and angiographic char-
acteristics excepting deployed stent length (20.822.9mm in ISR vs 31.925.7mm in
de novo group, p¼0.006) and used contrast dose (220.192.2ml in ISR vs
269.36111ml in de novo group, p¼0.003) between both groups. Success rate of
TLR was 80% of the ISR CTO group and 83.8% of de novo group (p¼0.50). In the
ISR CTO group, the success rate of re-stenosed drug eluting stent (DES) using
patients tended to be superior than that of re-stenosed bare metal stent (BMS) using
patients, but it's not signiﬁcant (85.7% vs 71.4%, p¼0.576). The 5-year MACCE-free
survival of ISR CTO group was signiﬁcantly lower than de novo group (61.6% vs
89.8%, p¼0.034). On multivariate analysis, ISR CTO was associated with higher
incidence of MACCE (hazard ratio 2.29, 95% conﬁdence interval 1.046 to 5.030).
Conclusions: Procedural success rate for ISR CTO lesion was similar to that of de
novo CTO lesion. But, ISR CTO group showed worse long term clinical prognosis
than de novo CTO group.
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Background: Up to 30% chronic total occlusions (CTO) cannot be revascularized by
conventional angioplasty. Therapeutic enhancement of the antegrade collateral
circulation may offer a novel solution. Previously, we investigated stimulation of
endothelial cell (EC) angiogenesis via stabilized hypoxia inducible factor (HIF)
utilizing two prolyl-hydroxylase inhibitors. We reported di-methyl oxalylglycine
(DMOG) increased collateral neovascularization in a porcine CTO model and showed
BIQ(FG-2216), trialled for use in man for alternative indications, induced a dose-
dependent pro-angiogenic response in primary human EC in vitro. We now report
molecular mechanisms underlying the novel action of BIQ.
Methods: Human umbilical vein ECs (HUVECs) were treated with 500mM BIQ for
up to 24 hours. (100mM CoCl2 was used as a positive control for HIF-1a stabiliza-
tion). Expression of HIF-1a protein from cell lysates was analyzed by WesternJACC Vol 62/18S1/Suppl B j October 27–November 1, 2013 j TCT Abblotting. Quantitative PCR was used to examine the expression of vascular endothelial
cell growth factor (VEGF) mRNA from treated EC.
Results: Stabilization of HIF-1a protein was demonstrated in EC after treatment with
BIQ, along with a 1.45 fold increase in VEGF mRNA expression, after one hour of
treatment (Figure).Conclusions: We have conﬁrmed that BIQ(FG-2216) upregulates HIF-1a in EC and
shown evidence for a mechanism involving the angiogenic factor VEGF; important if
we plan to translate this therapy. On-going work includes the deployment of polymer-
coated BIQ eluting stents with in vitro and in vivo evaluation to develop an effective
treatment for difﬁcult CTOs in man.
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Background: The hybrid approach to coronary chronic total occlusion (CTO)
crossing was developed to optimize procedural efﬁcacy, efﬁciency, and safety.
Methods: We examined the procedural techniques and outcomes of 287 consecutive
CTO cases performed using the hybrid approach between August 2011 and June 2013
at 4 US centers: Appleton Cardiology, Appleton Wisconsin; St. Joseph Medical
Center, Bellingham Washington; St. Luke's Health System's Mid-America Heart
Institute, Kansas City, Missouri; and VA North Texas Healthcare System, Dallas,
Texas.
Results:Mean age was 64.410.2 years and 89% of the patients were men, with high
prevalence of diabetes mellitus (45%), peripheral arterial disease (17%), prior
percutaneous coronary intervention (60%) and prior coronary artery bypass graft
surgery (36%). Most target CTOs were located in the right coronary artery (60%),
followed by the left anterior descending artery (21%), left circumﬂex (17%), posterior
descending artery (1%) and left main coronary artery (1%). Dual injection was used in
74%. Overall, antegrade wire escalation was used in 63%, antegrade dissection re-
entry in 38% and retrograde in 45%. Among successful cases, the ﬁnal successful
crossing technique was antegrade wire escalation in 41%, antegrade dissection an re-
entry in 27%, and retrograde in 32%. The initial crossing strategy was successful in
60% of the patients, whereas 33% required an additional 1 to 4 crossing strategies.
Technical success was achieved in 93% and major procedural complications occurred
in 2% (death in 2 patients, one due to tamponade and one due to vascular access
complication; and myocardial infarction in 3 patients). Mean contrast volume, ﬂuo-
roscopy time, and air kerma radiation exposure were 275.2149.0 ml, 45.930.7
minutes, and 3.872.25 Gray, respectively.
Conclusions: Application of the hybrid strategy to CTO crossing resulted in high
success and low complication rates among a varied operator group and hospital
structure, further supporting the value of the hybrid approach in crossing these
challenging coronary lesions.stracts/POSTER/Chronic Total Occlusions B119
